![Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download](https://images.slideplayer.com/30/9505354/slides/slide_4.jpg)
Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download
![A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine](https://www.thelancet.com/cms/asset/6e1783ac-334c-47ca-aa5f-14139b568e32/gr2.jpg)
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine
![Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The](https://www.thelancet.com/cms/attachment/2cbba9be-95f0-4764-ad55-25b5e2074383/gr1.gif)
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The
![Frontiers | What Is Long-Term Survival and Which First-Line Immunotherapy Brings Long-Term Survival for Advanced Wild-Type Non-Small Cell Lung Cancer: A Network Meta-Analysis Based on Integrated Analysis Frontiers | What Is Long-Term Survival and Which First-Line Immunotherapy Brings Long-Term Survival for Advanced Wild-Type Non-Small Cell Lung Cancer: A Network Meta-Analysis Based on Integrated Analysis](https://www.frontiersin.org/files/Articles/764643/fimmu-13-764643-HTML/image_m/fimmu-13-764643-g001.jpg)
Frontiers | What Is Long-Term Survival and Which First-Line Immunotherapy Brings Long-Term Survival for Advanced Wild-Type Non-Small Cell Lung Cancer: A Network Meta-Analysis Based on Integrated Analysis
![Definition of progression free survival and overall survival for the... | Download Scientific Diagram Definition of progression free survival and overall survival for the... | Download Scientific Diagram](https://www.researchgate.net/publication/265644752/figure/fig1/AS:269802786783234@1441337405030/Definition-of-progression-free-survival-and-overall-survival-for-the-Gold-standard-and_Q320.jpg)
Definition of progression free survival and overall survival for the... | Download Scientific Diagram
![Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology](https://www.thelancet.com/cms/attachment/f10fa33d-cf21-48d9-862f-0a70a29890a5/gr1_lrg.jpg)
Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology
![Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology](https://www.thelancet.com/cms/attachment/34b2410d-db54-46e1-ac1d-1d1894292938/gr1_lrg.gif)
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology
![Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis | The BMJ Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis | The BMJ](https://www.bmj.com/content/bmj/378/bmj-2022-070346/F2.medium.jpg)
Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis | The BMJ
![Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601 | Journal of Clinical Oncology Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601 | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2022/jco.2022.40.issue-27/jco.21.02741/20220907/images/large/jco.21.02741t3.jpeg)
Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601 | Journal of Clinical Oncology
![Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601 | Journal of Clinical Oncology Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601 | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2022/jco.2022.40.issue-27/jco.21.02741/20220907/images/large/jco.21.02741ta2.jpeg)
Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601 | Journal of Clinical Oncology
![Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley](https://acsjournals.onlinelibrary.wiley.com/cms/asset/7ec0391a-b577-4b44-aac8-535a76de8de5/cncr30934-fig-0001-m.jpg)